Evidence map›Paper›PMID 35267630›Full record

ArticleCancers2022

Extracorporeal Removal of Thermosensitive Liposomal Doxorubicin from Systemic Circulation after Tumor Delivery to Reduce Toxicities.

Anjan Motamarry, A Marissa Wolfe, Krishna K Ramajayam, Sanket Pattanaik, Thomas Benton, Yuri Peterson, Pegah Faridi, Punit Prakash, Katherine Twombley, Dieter Haemmerich

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 45% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 1 country.

Anjan MotamarryDepartment of Pediatrics, Medical University of South Carolina, Charleston, SC 29425, USA.ORCID 0000-0003-2964-9658
A Marissa WolfeRalph H. Johnson VA Medical Center, Charleston, SC 29425, USA.
Krishna K RamajayamDepartment of Pediatrics, Medical University of South Carolina, Charleston, SC 29425, USA.ORCID 0000-0002-9820-5842
Sanket PattanaikDepartment of Surgery, Medical University of South Carolina, Charleston, SC 29425, USA.
Thomas BentonDepartment of Drug Discovery & Biomedical Sciences, Medical University of South Carolina, Charleston, SC 29425, USA.
Yuri PetersonDepartment of Drug Discovery & Biomedical Sciences, Medical University of South Carolina, Charleston, SC 29425, USA.ORCID 0000-0002-4005-9678
Pegah FaridiDepartment of Electrical and Computer Engineering, Kansas State University, Manhattan, KS 66506, USA.
Punit PrakashDepartment of Electrical and Computer Engineering, Kansas State University, Manhattan, KS 66506, USA.ORCID 0000-0001-6467-722X
Katherine TwombleyDepartment of Pediatrics, Medical University of South Carolina, Charleston, SC 29425, USA.
Dieter HaemmerichDepartment of Pediatrics, Medical University of South Carolina, Charleston, SC 29425, USA.ORCID 0000-0003-1127-7024
Medical University of South Carolina · USKansas State University · USHarvard University · USRalph H. Johnson VA Medical Center · US

Funding

South Carolina Clinical & Translational Research Institute (SCTR)UL1TR001450 · NCATS · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI BRADY, KATHLEEN T., FLUME, PATRICK A · 2015 to 2024
$41.1M
In vivo derived in silico model for DDS optimizationR01CA181664 · NCI · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI Dieter Haemmerich · 2014 to 2026
$3.2M
EXTRAMURAL RESEARCH FACILITIES CONSTRUCTIONC06RR018823 · NCRR · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI RAYMOND, JOHN R · 2003 to 2003
$2.9M
MUSC FACIL EXPANSION &RENOV: SLE C06RR015455 · NCRR · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI RAYMOND, JOHN R · 2002 to 2002
$2.0M
Extracorporeal Filtration of Thermosensitive LiposomesR21CA249690 · NCI · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI HAEMMERICH, DIETER · 2021 to 2022
$384k
NIH HHS C06 RR015455NIH HHS C06 RR018823NIH HHS R21CA249690NIH HHS RO1CA181664NIH HHS UL1TR001450
6 · The paper itself

Abstract

Thermosensitive liposomal doxorubicin (TSL-Dox) combined with localized hyperthermia enables targeted drug delivery. Tumor drug uptake occurs only during hyperthermia. We developed a novel method for removal of systemic TSL-Dox remaining after hyperthermia-triggered delivery to reduce toxicities. The carotid artery and jugular vein of Norway brown rats carrying two subcutaneous BN-175 tumors were catheterized. After allowing the animals to recover, TSL-Dox was infused at 7 mg/kg dose. Drug delivery to one of the tumors was performed by inducing 15 min microwave hyperthermia (43 °C). At the end of hyperthermia, an extracorporeal circuit (ECC) comprising a heating module to release drug from TSL-Dox followed by an activated carbon filter to remove free drug was established for 1 h (

Indexed as

extracorporeal circulationhyperthermiathermosensitive liposomes

Identifiers

PMID35267630
PMCPMC8909191
OpenAlexW4220686098

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.